<p>隨着美國股市在符合預期的通脹數據發佈後上漲，投資者正密切關注各個行業的機會。儘管通常被視為過去交易日的遺物，便士股今天依然相關，因為它們在較低的價格點提供潛在的增長機會。本文探討了三隻展現財務實力和穩定性的有前景的便士股，為投資者提供了發掘優質公司隱藏價值的機會。</p>
<h3>美國十大便士股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.10</td>
<td>$447.9M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.99</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$5.00</td>
<td>$56.92M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Puma Biotechnology (PBYI)</td>
<td>$4.70</td>
<td>$237.75M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Sensus Healthcare (SRTS)</td>
<td>$3.13</td>
<td>$51.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.99</td>
<td>$25.49M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Table Trac (TBTC)</td>
<td>$4.50</td>
<td>$21.81M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9962</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$87M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股篩選器的 375 只股票的完整列表。</p>
<p>下面我們重點介紹幾隻我們獨家的篩選器中的最愛。</p>
<h2>Zenvia (ZENV)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Zenvia Inc. 運營一個基於雲的平台，提供跨多個國家的集成通信解決方案，市值為 7531 萬美元。</p>
<p><strong>運營：</strong> 公司通過兩個主要部門產生收入：SaaS，貢獻 3.2522 億雷亞爾，和 CPaaS，貢獻 7.7232 億雷亞爾。</p>
<p><strong>市值：</strong> $75.31M</p>
<p>Zenvia Inc. 的市值為 7531 萬美元，運營於基於雲的通信領域，展現出來自其 SaaS 和 CPaaS 部門的有前景的收入來源。儘管在 2025 年第二季度報告了 4198 萬雷亞爾的淨虧損，但它通過在五年內將債務與股本比率從 75.5% 降低到 12.5%，並保持正的自由現金流，現金流持續超過三年，改善了其財務狀況。然而，挑戰依然存在，因為短期負債超過資產，且收益波動性持續高於行業標準，儘管過去一年每週波動性穩定。</p>
<ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Zenvia 的表現。</li>
<li>通過我們的公司收益預估報告，獲取 Zenvia 的前景和預期表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 ZENV 的債務與股本歷史及分析</p>
<h2>Nautilus Biotechnology (NAUT)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家開發階段的生命科學公司，專注於創建一個平台技術，以量化和理解蛋白質組的複雜性，市值為 9095 萬美元。</p>
<p><strong>運營：</strong> 作為一家開發階段的公司，Nautilus Biotechnology 尚未報告任何收入部門。</p>
<p><strong>市值：</strong> $90.95M</p>
<p>Nautilus Biotechnology 的市值為 9095 萬美元，仍處於無收入階段，專注於開發蛋白質組分析技術。儘管在 2025 年第二季度報告了 1503 萬美元的淨虧損和上半年的 3165 萬美元淨虧損，但其財務健康狀況因短期資產（1.507 億美元）超過負債且無債務而得到增強。該公司最近與艾倫研究所建立了戰略聯盟，以探索 tau 蛋白在阿爾茨海默病進展中的作用，儘管預計未來三年收益將下降，現金流即使按歷史速度減少，現金流也將持續超過兩年。</p>
<ul>
<li>在我們的財務健康報告中更詳細地瞭解 Nautilus Biotechnology 的潛力。</li>
<li>通過查看我們的增長報告，獲取 Nautilus Biotechnology 未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 NAUT 的債務與股本歷史及分析</p>
<h2>Prelude Therapeutics (PRLD)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家臨牀階段的精準腫瘤學公司，致力於為服務不足的患者發現和開發新型癌症藥物，市值為 6905 萬美元。</p>
<p><strong>運營：</strong> Prelude Therapeutics 目前未報告任何收入部門。</p>
<p><strong>市值：</strong> $69.05M</p>
<p>Prelude Therapeutics 的市值為 6905 萬美元，處於無收入階段，專注於開發精準腫瘤學治療。該公司在 2025 年第二季度報告了 3123 萬美元的淨虧損，較去年同期的 3474 萬美元虧損有所改善，表明在管理費用方面略有進展。Prelude 保持無債務，短期資產（7690 萬美元）超過負債，但如果當前現金流趨勢持續，現金流將不足一年。儘管股價波動性高，預計未來三年收益將下降，但其經驗豐富的管理層和董事會在財務不確定性中提供了一定的穩定性。</p>
<ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 Prelude Therapeutics 的動態。</li>
<li>在這裏瞭解 Prelude Therapeutics 未來的增長軌跡。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 PRLD 的債務與股本歷史及分析</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>點擊這裏訪問我們完整的 375 只美國便士股票索引。</li>
<li>準備好採取不同的方法了嗎？這 13 家公司在 COVID 之後生存並蓬勃發展，具備應對特朗普關税的正確要素。在您的投資組合感受到貿易戰的壓力之前，瞭解原因。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

PRLD

ZENV

NAUT

<p>美國股市正在上漲，激發了對低價股的興趣，這些股票在較低價格下提供增長潛力。本文重點介紹了三隻有前景的低價股：Zenvia Inc.（市值 7531 萬美元）、Nautilus Biotechnology（市值 9095 萬美元）和 Prelude Therapeutics（市值 6905 萬美元）。儘管 Zenvia 出現了淨虧損，但其財務狀況有所改善；Nautilus 尚未產生收入，但無債務且擁有大量短期資產；Prelude 同樣尚未產生收入，但在管理費用方面略有改善。每家公司為投資者提供了獨特的機會和挑戰</p>

<p>As the U.S. stock market experiences a rise following inflation data that met expectations, investors are keenly watching for opportunities across various sectors. Though often seen as relics of past trading days, penny stocks remain relevant today by offering potential growth at lower price points. In this article, we explore three promising penny stocks that showcase financial strength and stability, providing investors with the opportunity to uncover hidden value in quality companies.</p>
<div class="lb-trans"><p>隨着美國股市在符合預期的通脹數據發佈後上漲，投資者正密切關注各個行業的機會。儘管通常被視為過去交易日的遺物，便士股今天依然相關，因為它們在較低的價格點提供潛在的增長機會。本文探討了三隻展現財務實力和穩定性的有前景的便士股，為投資者提供了發掘優質公司隱藏價值的機會。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.10</td>
<td>$447.9M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.99</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$5.00</td>
<td>$56.92M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Puma Biotechnology (PBYI)</td>
<td>$4.70</td>
<td>$237.75M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Sensus Healthcare (SRTS)</td>
<td>$3.13</td>
<td>$51.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.99</td>
<td>$25.49M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Table Trac (TBTC)</td>
<td>$4.50</td>
<td>$21.81M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9962</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$87M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.10</td>
<td>$447.9M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.99</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$5.00</td>
<td>$56.92M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Puma Biotechnology (PBYI)</td>
<td>$4.70</td>
<td>$237.75M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Sensus Healthcare (SRTS)</td>
<td>$3.13</td>
<td>$51.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.99</td>
<td>$25.49M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Table Trac (TBTC)</td>
<td>$4.50</td>
<td>$21.81M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9962</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$87M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 375 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股篩選器的 375 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我們重點介紹幾隻我們獨家的篩選器中的最愛。</p>
</div><h2>Zenvia (ZENV)</h2>
<div class="lb-trans"><h2>Zenvia (ZENV)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Zenvia Inc. operates a cloud-based platform facilitating integrated communication solutions across multiple countries, with a market cap of $75.31 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Zenvia Inc. 運營一個基於雲的平台，提供跨多個國家的集成通信解決方案，市值為 7531 萬美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through two primary segments: SaaS, contributing R$325.22 million, and CPaaS, accounting for R$772.32 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司通過兩個主要部門產生收入：SaaS，貢獻 3.2522 億雷亞爾，和 CPaaS，貢獻 7.7232 億雷亞爾。</p>
</div><p><strong>Market Cap:</strong> $75.31M</p>
<div class="lb-trans"><p><strong>市值：</strong> $75.31M</p>
</div><p>Zenvia Inc., with a market cap of $75.31 million, operates in the cloud-based communication sector, showing promising revenue streams from its SaaS and CPaaS segments. Despite reporting a net loss of BRL 41.98 million for Q2 2025, it has improved its financial position over time by reducing its debt to equity ratio from 75.5% to 12.5% in five years and maintaining a positive free cash flow with a cash runway exceeding three years. However, challenges remain as short-term liabilities surpass assets and earnings volatility persists above industry norms despite stable weekly volatility over the past year.</p>
<div class="lb-trans"><p>Zenvia Inc. 的市值為 7531 萬美元，運營於基於雲的通信領域，展現出來自其 SaaS 和 CPaaS 部門的有前景的收入來源。儘管在 2025 年第二季度報告了 4198 萬雷亞爾的淨虧損，但它通過在五年內將債務與股本比率從 75.5% 降低到 12.5%，並保持正的自由現金流，現金流持續超過三年，改善了其財務狀況。然而，挑戰依然存在，因為短期負債超過資產，且收益波動性持續高於行業標準，儘管過去一年每週波動性穩定。</p>
</div><ul>
<li>Get an in-depth perspective on Zenvia's performance by reading our balance sheet health report here.</li>
<li>Gain insights into Zenvia's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的資產負債表健康報告，深入瞭解 Zenvia 的表現。</li>
<li>通過我們的公司收益預估報告，獲取 Zenvia 的前景和預期表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis"/></p>
<p>ZENV Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 ZENV 的債務與股本歷史及分析</p>
</div><h2>Nautilus Biotechnology (NAUT)</h2>
<div class="lb-trans"><h2>Nautilus Biotechnology (NAUT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and understand the complexity of the proteome, with a market cap of $90.95 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家開發階段的生命科學公司，專注於創建一個平台技術，以量化和理解蛋白質組的複雜性，市值為 9095 萬美元。</p>
</div><p><strong>Operations:</strong> As a development stage company, Nautilus Biotechnology has not yet reported any revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> 作為一家開發階段的公司，Nautilus Biotechnology 尚未報告任何收入部門。</p>
</div><p><strong>Market Cap:</strong> $90.95M</p>
<div class="lb-trans"><p><strong>市值：</strong> $90.95M</p>
</div><p>Nautilus Biotechnology, with a market cap of US$90.95 million, remains pre-revenue, focusing on developing proteome analysis technology. Despite reporting net losses of US$15.03 million for Q2 2025 and US$31.65 million for the first half of the year, its financial health is bolstered by substantial short-term assets (US$150.7M) exceeding liabilities and being debt-free. The company recently entered a strategic alliance with the Allen Institute to explore tau proteins' role in Alzheimer's disease progression, highlighting potential scientific breakthroughs despite projected earnings declines over the next three years and a cash runway extending over two years even if cash flow reduces at historical rates.</p>
<div class="lb-trans"><p>Nautilus Biotechnology 的市值為 9095 萬美元，仍處於無收入階段，專注於開發蛋白質組分析技術。儘管在 2025 年第二季度報告了 1503 萬美元的淨虧損和上半年的 3165 萬美元淨虧損，但其財務健康狀況因短期資產（1.507 億美元）超過負債且無債務而得到增強。該公司最近與艾倫研究所建立了戰略聯盟，以探索 tau 蛋白在阿爾茨海默病進展中的作用，儘管預計未來三年收益將下降，現金流即使按歷史速度減少，現金流也將持續超過兩年。</p>
</div><ul>
<li>Take a closer look at Nautilus Biotechnology's potential here in our financial health report.</li>
<li>Gain insights into Nautilus Biotechnology's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更詳細地瞭解 Nautilus Biotechnology 的潛力。</li>
<li>通過查看我們的增長報告，獲取 Nautilus Biotechnology 未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>NAUT Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 NAUT 的債務與股本歷史及分析</p>
</div><h2>Prelude Therapeutics (PRLD)</h2>
<div class="lb-trans"><h2>Prelude Therapeutics (PRLD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $69.05 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家臨牀階段的精準腫瘤學公司，致力於為服務不足的患者發現和開發新型癌症藥物，市值為 6905 萬美元。</p>
</div><p><strong>Operations:</strong> Prelude Therapeutics does not currently report any revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Prelude Therapeutics 目前未報告任何收入部門。</p>
</div><p><strong>Market Cap:</strong> $69.05M</p>
<div class="lb-trans"><p><strong>市值：</strong> $69.05M</p>
</div><p>Prelude Therapeutics, with a market cap of US$69.05 million, is pre-revenue and focused on developing precision oncology treatments. The company reported a net loss of US$31.23 million for Q2 2025, an improvement from the previous year's loss of US$34.74 million, indicating slight progress in managing expenses. Prelude remains debt-free with short-term assets (US$76.9M) exceeding liabilities, but faces challenges with less than a year of cash runway if current cash flow trends persist. Despite high share price volatility and forecasted earnings declines over the next three years, its experienced management and board offer some stability amidst financial uncertainties.</p>
<div class="lb-trans"><p>Prelude Therapeutics 的市值為 6905 萬美元，處於無收入階段，專注於開發精準腫瘤學治療。該公司在 2025 年第二季度報告了 3123 萬美元的淨虧損，較去年同期的 3474 萬美元虧損有所改善，表明在管理費用方面略有進展。Prelude 保持無債務，短期資產（7690 萬美元）超過負債，但如果當前現金流趨勢持續，現金流將不足一年。儘管股價波動性高，預計未來三年收益將下降，但其經驗豐富的管理層和董事會在財務不確定性中提供了一定的穩定性。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of Prelude Therapeutics.</li>
<li>Learn about Prelude Therapeutics' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整財務健康分析報告，以瞭解 Prelude Therapeutics 的動態。</li>
<li>在這裏瞭解 Prelude Therapeutics 未來的增長軌跡。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>PRLD Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 PRLD 的債務與股本歷史及分析</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Click here to access our complete index of 375 US Penny Stocks.</li>
<li>Ready For A Different Approach? These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 375 只美國便士股票索引。</li>
<li>準備好採取不同的方法了嗎？這 13 家公司在 COVID 之後生存並蓬勃發展，具備應對特朗普關税的正確要素。在您的投資組合感受到貿易戰的壓力之前，瞭解原因。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

3 只市值超過 6000 萬美元的有潛力的便士股